Hasley Ike B, Bies Michael M, Hollman John H, Carta Karina Gonzales, Sellon Jacob L, Brault Jeffrey S
Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN.
Division of Sports Medicine, Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN.
Arch Rehabil Res Clin Transl. 2023 Jan 29;5(1):100257. doi: 10.1016/j.arrct.2023.100257. eCollection 2023 Mar.
To assess the effects of platelet-rich plasma (PRP) injection among patients with thumb carpometacarpal (CMC) joint osteoarthritis (OA).
Retrospective chart review with follow-up questionnaires/surveys. Post-procedure, patients were sent standardized, automatically-generated follow-up questionnaires, and contacted for a survey regarding patient-reported outcomes.
Single institution (tertiary care hospital) outpatient clinic from 2015 to 2020.
Nineteen adult patients (9 women; average age 65.0 [±6.3 years]) who received a PRP injection for OA of 1 or both thumb CMCs (N=19).
Platelet-rich plasma injection.
Outcome measures included symptom improvement (subjective, visual analog scale), duration of benefit, subsequent procedures, satisfaction, and side effects/adverse events. Cellular composition of whole blood and PRP injectate (platelets, erythrocytes, leukocytes, neutrophils, lymphocytes, and monocytes) were analyzed.
Subjects reported moderate or excellent symptom improvement in 68.8% of injected joints and were moderately or very satisfied with 68.8% of the procedures. Mean patient-reported duration of benefit was 15.6 months (±19.5) months (mean duration of follow-up: 32.4 [±18.1] months). There were no major complications attributed to the procedures, but 1 patient was diagnosed with presumed unrelated lymphoma 2 weeks post-procedure. PRP mean platelet concentration was 1787.77 (±687.14) × 10/L, resulting in a mean platelet concentration factor of 8.80 (±4.19) times baseline and mean platelet dose of 1881 × 10. Other PRP cell concentration factors were erythrocytes, 0.02; neutrophils, 0.14; lymphocytes, 3.76; and monocytes, 3.29.
PRP injection appears to be a safe and potentially effective treatment option for pain related to first CMC OA. Further study is needed to optimize treatment protocols and better understand which patients are most likely to benefit.
评估富血小板血浆(PRP)注射对拇指腕掌关节(CMC)骨关节炎(OA)患者的疗效。
采用回顾性病历审查并结合随访问卷/调查。术后,向患者发送标准化的自动生成的随访问卷,并就患者报告的结果进行调查。
2015年至2020年的单一机构(三级护理医院)门诊诊所。
19名成年患者(9名女性;平均年龄65.0[±6.3岁]),因1个或双侧拇指CMC的OA接受了PRP注射(N = 19)。
富血小板血浆注射。
观察指标包括症状改善(主观视觉模拟量表)、受益持续时间、后续治疗、满意度以及副作用/不良事件。分析了全血和PRP注射剂的细胞组成(血小板、红细胞、白细胞、中性粒细胞、淋巴细胞和单核细胞)。
受试者报告68.8%的注射关节症状有中度或显著改善,68.8%的治疗患者中度或非常满意。患者报告的平均受益持续时间为15.6个月(±19.5个月)(平均随访时间:32.4[±18.1]个月)。该治疗未出现重大并发症,但有1例患者在术后2周被诊断为疑似无关的淋巴瘤。PRP平均血小板浓度为1787.77(±687.14)×10/L,平均血小板浓度因子为基线的8.80(±4.19)倍,平均血小板剂量为1881×10。其他PRP细胞浓度因子为红细胞0.02;中性粒细胞0.14;淋巴细胞3.76;单核细胞3.29。
PRP注射似乎是治疗第一CMC OA相关疼痛的一种安全且可能有效的治疗选择。需要进一步研究以优化治疗方案,并更好地了解哪些患者最可能受益。